Keyphrases
Pharmacokinetics
72%
Population Pharmacokinetics
21%
Therapeutic Drug Monitoring
19%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
16%
Confidence Interval
16%
Pediatric Patients
15%
Pemetrexed
15%
Human Plasma
15%
Non-small Cell Lung Cancer Patients
12%
Treatment Outcome
11%
Clinical Pharmacology
11%
Aprepitant
11%
Neonate
11%
Human Serum
11%
Ritonavir
11%
Plasma Concentration
10%
Cisplatin
10%
Clinical Practice
9%
Olaparib
9%
Chemotherapy Toxicity
9%
Pharmacodynamics
9%
Oncology
9%
Drug Use
8%
Pharmacokinetic Study
8%
Systematic Meta-analysis
8%
Physiologically-based Pharmacokinetic Model
7%
Phase II Study
7%
Skeletal muscle Mass
7%
Chemotherapy
7%
Precision Dosing
7%
Poverty-related Diseases
7%
Pharmacogenomics
7%
Xanthine
7%
Hypoxanthine
7%
Osimertinib
7%
Kinase Inhibitor
7%
Proof of Concept Study
7%
Oral Anticancer Drugs
7%
Malnutrition
7%
Thyroid Cancer
7%
Therapeutic Monoclonal Antibody
7%
Docetaxel
7%
Overall Survival
7%
Low muscle Mass
7%
Dosing Regimen
7%
Active Metabolite
7%
Randomized Controlled Trial
6%
Pediatric Oncology
6%
Lorlatinib
6%
Hypoxic-ischemic Encephalopathy
6%
Allopurinol
6%
Optimized Dosing
6%
Renal Function
6%
Modeling Approach
6%
Meta-analysis
6%
Therapeutic Agents
6%
Non-small Cell Lung Cancer (NSCLC)
5%
High Risk
5%
Emicizumab
5%
Cytochrome P450 3A (CYP3A)
5%
Busulfan
5%
Gemcitabine
5%
Drug Interactions
5%
Dose-limiting Toxicity
5%
Cytotoxic Drugs
5%
Cytochrome P450 3A4 (CYP3A4)
5%
Sunitinib
5%
Clinical Outcomes
5%
Non-compartmental Analysis
5%
Radiotherapy
5%
PARP Inhibitor (PARPi)
5%
Adaptation
5%
Ipilimumab
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Chemotherapy
22%
Therapeutic Drug Monitoring
18%
Non Small Cell Lung Cancer
16%
Pharmacodynamics
15%
Pemetrexed
15%
Malignant Neoplasm
13%
Vincristine
13%
Anticarcinogen
12%
Aprepitant
11%
Ritonavir
11%
Cisplatin
10%
Pharmacokinetic Modeling
10%
Randomized Controlled Trial
9%
Childhood Cancer
8%
Paclitaxel
8%
Tolerability
8%
Biological Marker
8%
Overall Survival
7%
Thyroid Cancer
7%
Osimertinib
7%
Epidermal Growth Factor Receptor
7%
Breast Cancer
7%
Pharmacogenomics
7%
Dexamethasone
7%
Allopurinol
7%
Xanthine
7%
Uric Acid
7%
Hypoxanthine
7%
Hypoxic Ischemic Encephalopathy
7%
Phosphotransferase Inhibitor
7%
Docetaxel
7%
Active Metabolite
7%
Neoplasm
6%
Drug-Drug Interaction
6%
Busulfan
6%
Creatinine
6%
Lorlatinib
6%
CYP3A4
5%
Olaparib
5%
Gemcitabine
5%
Progression Free Survival
5%
Pharmacogenetics
5%
Neuropathy
5%
CYP3A
5%
Cytotoxic Agent
5%
Sunitinib
5%
Fludarabine
5%
Oxypurinol
5%